Your account is not claimed yet. You can sign up with ORCID to claim your account.

Sumati V Gupta (Sumati Gupta)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 14

Top Venues

BMC research notes

Journal for immunotherapy of cancer

JCO precision oncology

Familial cancer

Huntsman Cancer Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Huntsman Cancer Institute Oct 23o 2014

United States

Faculty :: Medical Oncology

Publications

Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman, Sumati V Gupta
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer 11 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman, Sumati V Gupta
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer 11 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman, Sumati V Gupta
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer 11 (1) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Deborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, Sumati V Gupta, Ulka N Vaishampayan, Elisabeth I Heath, Philip Garcia, Qianqian Zhao, Menggang Yu, Matthew I Milowsky, Matthew D Galsky
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO precision oncology 7 (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Rom S Leidner, Kevin C Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati V Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O'Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for immunotherapy of cancer 11 (10) (2023)
Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth M Boucher, James Marvin, Josiah Hawks, William Burnett, Matthew Van Brocklin, Jonathan Whisenant, Glynn Gilcrease, Sumati V Gupta
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes 16 (1) (2023)
Kevin C Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William Douglas Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati V Gupta, Rom S Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer 9 (11) (2022)
Sumati V Gupta, Samantha Greenberg, Jade Grimmett, David Gaston, Neeraj Agarwal, William Lowrance, Joshua Schiffman, Wendy Kohlmann
Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Familial cancer 16 (4) (2018)
Sumati V Gupta, Launce Gouw, Jennifer Wright, Sant Chawla, Debbie Pitt, Mark Wade, Ken Boucher, Sunil Sharma
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Investigational new drugs 34 (2) (2016)

Sumati V Gupta.css-eqlu8i{font-size:small;padding-left:4px;} (Sumati Gupta)

Publication Activity (10 Years)

Top Topics

Top Venues

Sumati V Gupta (Sumati Gupta)